Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Weaver | M | - |
PetMedix Ltd.
 PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | 6 years |
| Timothy James Rink | M | 78 |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Erwin Boos | M | 46 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Alf Gunnar Martin Nicklasson | M | 69 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 7 years |
| Alan Bradley | M | 64 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | - |
| Tan Li | F | 60 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Christian Itin | M | 59 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Timothy Nigel Carl Wells | M | 62 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Simone Song | F | 59 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Jolyon Martin | M | 53 |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | 6 years |
| Douglas Fearon | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Volker Germaschewski | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Samuel Bjork | M | - |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | - |
| Fabian Kausche | M | - |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | 5 years |
| Alastair Kilgour | M | - |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | - |
| Robert Tansley | M | 61 |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | - |
| Jasper Clube | M | 56 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Nigel Clark | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Glenn Alfons Friedrich | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Paul Kellam | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kirk Chin Kee | M | 62 |
University of Cambridge
| 8 years |
| Khaled Asad Nasr | M | 66 |
University of Cambridge
| 3 years |
| R. Dominic King-Smith | M | - |
University of Cambridge
| 7 years |
| Simon Sturge | M | 65 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 2 years |
| Tony Alves | M | 62 |
University of Cambridge
| 6 years |
| Martin Roper | M | 61 |
University of Cambridge
| 5 years |
| Jonathan Mark Huntley | M | - |
University of Cambridge
| 8 years |
| Teck Huat Tan | M | 63 |
University of Cambridge
| 4 years |
| Luca Anderlini | M | 66 |
University of Cambridge
| 5 years |
| Mark Borwick | M | - |
University of Cambridge
| 3 years |
| Jean-Michel Cossery | M | 65 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | 3 years |
| John Simon Hunt | M | 61 |
University of Cambridge
| 4 years |
| Geoffrey G. Davis | M | - |
University of Cambridge
| 7 years |
| Hwee Hua Lim | F | 65 |
University of Cambridge
| 6 years |
| Paula Disberry | F | 56 |
University of Cambridge
| 5 years |
| Michael Owen | M | 73 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 1 years |
| Kin Wah Mak | M | 67 |
University of Cambridge
| 4 years |
| Michael John Wilson | M | - |
University of Cambridge
| 8 years |
| Ram shenoy | M | - |
University of Cambridge
| 3 years |
| Anne Philomena Hyland | F | 64 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 6 years |
| Alastair K. Livesey | M | 67 |
University of Cambridge
| 3 years |
| Anthony Ian Walker | M | - |
University of Cambridge
| 6 years |
| David Chiswell | M | 70 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 4 years |
| Beatriz Pessoa de Araujo | F | - |
University of Cambridge
| 7 years |
| Christian Gröndahl | M | 60 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Angus Porter | M | 67 |
University of Cambridge
| 4 years |
| Roy Merritt | M | 60 |
University of Cambridge
| 4 years |
| Paul J. Carter | M | - |
University of Cambridge
| 8 years |
| Chong Kiat Lim | M | 68 |
University of Cambridge
| 7 years |
| Julian Healy | M | 62 |
University of Cambridge
| 5 years |
| Andrew Peter Sandham | M | 69 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Hugh Anthony Simons | M | - |
University of Cambridge
| 3 years |
| Graham Keniston-Cooper | M | - |
University of Cambridge
| 4 years |
| Stephen Johnson | M | 61 |
University of Cambridge
| 5 years |
| Robert Robinson | M | - |
University of Cambridge
| 3 years |
| Peter Foster | M | 64 |
University of Cambridge
| 4 years |
| Christopher A. Grew | M | - |
University of Cambridge
| 4 years |
| Michael Ellis | M | - |
University of Cambridge
| 4 years |
| Kwok-Kuen Leong | M | 63 |
University of Cambridge
| 4 years |
| Gerard Evan | M | - |
University of Cambridge
| 4 years |
| Robert Hanka | M | - |
University of Cambridge
| 3 years |
| Dennis Mulhaupt | M | - |
University of Cambridge
| 3 years |
| David Wilson Thomas Newcombe | M | 64 |
University of Cambridge
| 1 years |
| Tan Meng | M | 66 |
University of Cambridge
| 3 years |
| Peter Hobson | M | - |
University of Cambridge
| 3 years |
| John Paskin | M | - |
University of Cambridge
| 3 years |
| Tun Ho Kwok | M | 61 |
University of Cambridge
| 4 years |
| Jeremy Oppenheim | M | 62 |
University of Cambridge
| - |
| Jonathan Treherne | M | 63 |
University of Cambridge
| 3 years |
| Zainun binti Ali | F | 72 |
University of Cambridge
| 3 years |
| Nick Goddard | M | - |
University of Cambridge
| 3 years |
| Jem Davies | M | - |
University of Cambridge
| 3 years |
| Woon Kwong Seow | M | 63 |
University of Cambridge
| 4 years |
| Steve M. Hobbs | M | - |
University of Cambridge
| 4 years |
| Tong Boon Quek | M | 68 |
University of Cambridge
| 1 years |
| Donal Donat Conor Bradley | M | 62 |
University of Cambridge
| 3 years |
| Ian Hunter | M | - |
University of Cambridge
| 4 years |
| David E. Gill | M | - |
University of Cambridge
| 4 years |
| Simon Williams | M | - |
University of Cambridge
| 3 years |
| Jim Warwick | M | 59 |
University of Cambridge
| 2 years |
| Howard Chase | M | 70 |
University of Cambridge
| 22 years |
| S. Ross Penney | M | 60 |
University of Cambridge
| 4 years |
| James Anthony McNaught-Davis | M | 65 |
University of Cambridge
| 2 years |
| Christopher Abell | M | - |
University of Cambridge
| 3 years |
| Susannah Clements | F | - |
University of Cambridge
| 4 years |
| William Spurgin | M | - |
University of Cambridge
| 4 years |
| Andrew Hewson | M | 65 |
University of Cambridge
| 3 years |
| Andy M. Thompson | M | - |
University of Cambridge
| 3 years |
| Clive Partridge | M | - |
University of Cambridge
| 4 years |
| Ronjon Nag | M | - |
University of Cambridge
| 4 years |
| Mike Aspinwall | M | - |
University of Cambridge
| 4 years |
| Alan James Proto | M | 57 |
University of Cambridge
| 4 years |
| Adrian Eastwood | M | 63 |
University of Cambridge
| 4 years |
| Keith Philip Watkins | M | - |
University of Cambridge
| 3 years |
| Andrew Broomhead | M | 63 |
University of Cambridge
| 4 years |
| Patrice de Viviès | M | - |
University of Cambridge
| 4 years |
| David Checkel | M | - |
University of Cambridge
| 2 years |
| Osvaldo Pitters | M | - |
University of Cambridge
| 1 years |
| Dong-Gun Kim | M | 77 |
University of Cambridge
| 3 years |
| Shoong Tat Cheng | M | 63 |
University of Cambridge
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Allan Bradley
- Personal Network
